Human immunodeficiency virus (HIV) infection remains one of the biggest health burdens worldwide, affecting 36.9 million people (World Health Organisation, 2017). Venous thromboembolism (VTE) has a reported incidence of 0.19–7.63% in those with HIV, representing a 2–10 fold increase compared to the general population (Bibas et al, 2011; Rasmussen et al, 2011).